ULURU Inc. Announces Extensive Clinical Evidence Presented at the 24th Annual 'Clinical Symposium on Advances in Skin and Wound
22 October 2009 - 1:54AM
PR Newswire (US)
-Symposium to Feature 16 Poster Presentations on the Clinical
Results of Altrazeal(TM) ADDISON, Texas, Oct. 21
/PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today
announced that there will be 16 poster presentations featuring
clinical and pharmacoeconomic results at the 24th Annual "Clinical
Symposium on Advances in Skin and Wound Care" to be held in San
Antonio, Texas from October 22-25. The posters are being presented
by seven different clinical groups and highlight the benefits of
using Altrazeal(TM) in numerous wound types including, diabetic
foot ulcers, venous ulcers, trauma skin graft donor sites, skin
graft protection, surgical wounds and degenerative skin diseases.
Jim Gleaves M.D., surgeon, Rush Hospital, Meridian, Mississippi who
is presenting a poster at the conference stated "Altrazeal(TM) is
the most 'universal' wound dressing I have ever encountered in
nearly 40 years of practice." There are numerous important findings
that are demonstrated in these poster presentations: -- Evidence of
accelerated wound healing in the following wounds -- Diabetic Foot
Ulcers -- Venous Ulcers -- Trauma Induced Chronic Wounds --
Surgical Wounds -- Degenerate Skin Diseases -- Controlled clinical
study showing a statistically significant reduction in pain --
Evidence of significant pain reduction and quality of life
improvements across multiple wound types -- Evidence of
pharmacoeconomic benefits principally resulting from: -- Decreased
dressing changes -- Less frequent nursing visits -- Accelerated
healing Also discussed in the poster presentations are the
potential benefits to be derived from using Altrazeal(TM) in
combination with active pharmaceutical ingredients. Physicians have
experimented with positive results combining Altrazeal(TM) with
products including iodine and triamcinolone. Commenting on the
poster presentations, Renaat Van den Hooff, President and CEO of
ULURU Inc. stated, "This extensive series of poster presentation of
Altrazeal(TM) clearly demonstrates the clinical, economic and
patient benefits that can be derived from using Altrazeal(TM). This
clinical data shows benefits in the treatment of a wide variety of
wound types. As we continue to accumulate additional clinical data
the evidence of accelerated healing and reduction in pain and
improved patient benefits is becoming extremely compelling giving
us a very favorable product profile." Altrazeal(TM), a transforming
powder dressing which is produced using our patented Nanoflex(TM)
Technology, is suitable for exuding wounds such as burns,
abrasions, trauma, skin graft donor sites, surgical wounds and
chronic slow-healing wounds such as diabetic foot ulcers, pressure
ulcers and venous ulcers. Altrazeal(TM) is an innovative
breakthrough, designed for greater effectiveness in wound closure
by promoting an optimal moist wound healing environment, reducing
pain and enhancing patient comfort, ease of application and removal
and, in most cases, not requiring a secondary dressing. Renaat Van
den Hooff continued, "This is the first time that clinical evidence
has demonstrated the pharmacoeconomic benefits of Altrazeal(TM).
Given the drive to reduce health care costs we believe that this is
a very important finding which favorably positions Altrazeal(TM) in
the market place. We intend to continue to demonstrate the patient
and economic benefits that can be derived using Altrazeal(TM) for
the treatment of many chronic and acute wounds. By generating
additional data that supports these findings we believe that we can
clearly differentiate Altrazeal(TM) in the market place and
significantly decrease the cost associated with wound care." The
24th Annual "Clinical Symposium on Advances in Skin and Wound Care"
will be held on October 22-25, 2009 at the Grand Hyatt San Antonio
and the Henry B. Gonzalez Convention Center in San Antonio, Texas.
For more information about the conference please visit
http://www.symposiumonwoundcare.com/. About ULURU Inc.: ULURU Inc.
is a specialty pharmaceutical company focused on the development of
a portfolio of wound management and oral care products to provide
patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative Nanoflex(TM) Aggregate
technology and OraDisc(TM) transmucosal delivery system. For
further information about ULURU Inc., please visit our website at
http://www.uluruinc.com/. For further information about
Altrazeal(TM), please visit http://www.altrazeal.com/. This press
release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to
the benefits, effectiveness, success in wound healing, clinical
outcomes, and suitability of Altrazeal(TM), pharmacoeconomic
benefits and the success of our clinical efforts. These statements
are subject to numerous risks and uncertainties, including but not
limited to the risk factors detailed in the Company's Annual Report
on Form 10-K for the year ended December 31, 2008, and other
reports filed by us with the Securities and Exchange Commission.
Contact: Company Renaat E. Van den Hooff President & CEO Terry
K. Wallberg Vice President & CFO (214) 905-5145 DATASOURCE:
ULURU Inc. CONTACT: Renaat E. Van den Hooff, President & CEO,
or Terry K. Wallberg, Vice President & CFO, both of ULURU Inc.,
+1-214-905-5145 Web Site: http://www.uluruinc.com/
Copyright